Literature DB >> 25500117

Elderly benzodiazepine users at increased risk of activity limitations: influence of chronicity, indications, and duration of action--the three-city cohort.

Isabelle Carrière1, Thibault Mura2, Karine Pérès3, Joanna Norton2, Isabelle Jaussent2, Arlette Edjolo3, Olivier Rouaud4, Claudine Berr2, Karen Ritchie5, Marie Laure Ancelin2.   

Abstract

OBJECTIVE: To examine the cross-sectional and longitudinal associations between benzodiazepine use and daily activity limitations, according to drug indications and duration of action.
DESIGN: Prospective cohort study.
SETTING: Population-based three-city study. PARTICIPANTS: 6,600 participants aged 65 years and over included between 1999 and 2001 and followed after 2, 4, and 7 years. MEASUREMENTS: Benzodiazepine users were separated into hypnotic, short-acting anxiolytic, and long-acting anxiolytic users and compared with non users. Three outcomes were examined assessing restrictions in mobility, instrumental activities of daily living (IADLs) and social participation.
RESULTS: In multivariate simple or mixed logistic models adjusted for sociodemographic variables, impairments and comorbidity, and for anxiety, insomnia, and depression, hypnotic benzodiazepines were moderately associated with mobility limitation prevalence and IADL limitation incidence. Short-acting and long-acting anxiolytics were associated with IADL limitation prevalence and with mobility limitation prevalence and incidence and long-acting anxiolytics were also associated with IADL limitation incidence. Chronic benzodiazepines users were at a marked risk of developing restrictions for the three outcomes; odds ratio: 1.71 (95% CI: 1.23-2.39) for mobility, 1.54 (95% CI: 1.14-2.10) for IADL, and 1.74 (95% CI: 1.23-2.47) for participation limitations.
CONCLUSIONS: Benzodiazepine users are at increased risk of activity limitations regardless of the duration of action or indication. Chronic use of benzodiazepines should be avoided in order to extend disability-free survival.
Copyright © 2015 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Benzodiazepines; activity of daily living; aging; longitudinal study; random-effect model

Mesh:

Substances:

Year:  2014        PMID: 25500117     DOI: 10.1016/j.jagp.2014.10.006

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  6 in total

Review 1.  A Systematic Review of Opioid and Benzodiazepine Misuse in Older Adults.

Authors:  Rachel D Maree; Zachary A Marcum; Ester Saghafi; Debra K Weiner; Jordan F Karp
Journal:  Am J Geriatr Psychiatry       Date:  2016-06-07       Impact factor: 4.105

Review 2.  Attitudes Toward Use of Benzodiazepines among U.S. Hospice Clinicians: Survey and Review of the Literature.

Authors:  Andrew Kamell; Lauren Kelley Smith
Journal:  J Palliat Med       Date:  2016-03-22       Impact factor: 2.947

3.  Medication management issues identified during home medication reviews for ambulatory community pharmacy patients.

Authors:  John Papastergiou; Mathew Luen; Simona Tencaliuc; Wilson Li; Bart van den Bemt; Sherilyn Houle
Journal:  Can Pharm J (Ott)       Date:  2019-07-29

4.  Use of psychoactive drugs predicts functional disability among older adults.

Authors:  Denise Mourão Falci; Juliana Vaz de Melo Mambrini; Érico Castro-Costa; Josélia Oliveira Araújo Firmo; Maria Fernanda Lima-Costa; Antônio Ignácio de Loyola Filho
Journal:  Rev Saude Publica       Date:  2019-01-31       Impact factor: 2.106

5.  Comparisons Between Successful Versus Unsuccessful Switches From Benzodiazepines or Zolpidem (Z-Drug) to Controlled-Release Melatonin in Patients With Major Depressive Disorder and Insomnia.

Authors:  Ji Hyun An; Mi Jin Park; Maurizio Fava; David Mischoulon; Hyewon Kim; Jihoon Jang; Jin Pyo Hong; Jun Sang Park; Hong Jin Jeon
Journal:  Front Psychiatry       Date:  2020-05-19       Impact factor: 4.157

6.  Benzodiazepines utilization in Brazilian older adults: a population-based study.

Authors:  Marina de Borba Oliveira Freire; Bruna Gonçalves Cordeiro Da Silva; Andréa Dâmaso Bertoldi; Andréia Turmina Fontanella; Sotero Serrate Mengue; Luiz Roberto Ramos; Noemia Urruth Leão Tavares; Tatiane da Silva Dal Pizzol; Paulo Sérgio Dourado Arrais; Mareni Rocha Farias; Vera Lucia Luiza; Maria Auxiliadora Oliveira; Ana Maria Baptista Menezes
Journal:  Rev Saude Publica       Date:  2022-03-21       Impact factor: 2.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.